JCR Pharmaceuticals Co (TSE:4552) Net Income From Continuing Operations : 円5,507 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is JCR Pharmaceuticals Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. JCR Pharmaceuticals Co's net income from continuing operations for the three months ended in Dec. 2023 was 円-88 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was 円5,507 Mil.

JCR Pharmaceuticals Co Net Income From Continuing Operations Historical Data

The historical data trend for JCR Pharmaceuticals Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JCR Pharmaceuticals Co Net Income From Continuing Operations Chart

JCR Pharmaceuticals Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Net Income From Continuing Operations

Get a 7-Day Free Trial

3,422.00

8,653.00

19,404.00

5,412.00

5,507.00

JCR Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															202.00	1,607.00	3,653.00	-88.00	335.00

JCR Pharmaceuticals Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円5,507 Mil.

JCR Pharmaceuticals Co (TSE:4552) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JCR Pharmaceuticals Co Ltd (TSE:4552) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

JCRRF:USA

Address

3-19 Kasuga-cho, Ashiya, Hyogo, JPN, 659-0021

Website

http://www.jcrpharm.co.jp

JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.

JCR Pharmaceuticals Co (TSE:4552) Headlines

No Headlines